RT Journal Article
SR Electronic
T1 Exacerbation burden in mild asthma: Evidence from the NOVELTY study
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP 969
DO 10.1183/13993003.congress-2020.969
VO 56
IS suppl 64
A1 Sarowar Muhammad Golam
A1 Mohsen Sadatsafavi
A1 Marianna Alacqua
A1 Richard Beasley
A1 J Mark Fitzgerald
A1 Tim Harrison
A1 Rod Hughes
A1 Hana Müllerová
A1 Jose Maria Olaguibel
A1 Eleni Rapsomaniki
A1 Helen K Reddel
A1 Christer Janson
YR 2020
UL http://erj.ersjournals.com/content/56/suppl_64/969.abstract
AB Background: Although 50–75% of patients with asthma are reported to have mild asthma, exacerbations may still play a significant role in their disease burden. NOVELTY (NCT02760329) is a global, prospective, observational study of patients with a physician-assigned diagnosis of asthma and/or COPD. Physicians were asked to classify asthma as mild, moderate or severe; no criteria were provided.Objective: To describe the exacerbation burden of patients with physician-assessed mild asthma in the NOVELTY study.Methods: Baseline characteristics of patients with physician-assessed mild asthma were described.Results: Baseline characteristics for 2,175 patients with physician-assessed mild asthma (of 5,940 with asthma) were reported (Table). By physician report, in the past 12 months 527 patients (24%) had ≥1 exacerbation; mean exacerbation rate was 0.4 events/year. Healthcare resource utilisation data were available for 714/867 physician-reported exacerbations; 8% lasted for >1 month and 50% required oral corticosteroids (OCS). By patient report (n=1,494), 835 patients (56%) reported symptom worsening in the past 3 months; 25% of these patients received OCS for symptom worsening (for >2 weeks in 15% of patients who received OCS).Conclusions: In NOVELTY, many patients with physician-assessed mild asthma had a high exacerbation burden; one in four had ≥1 exacerbation in the past 12 months, and OCS was used in half of exacerbations.FootnotesCite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 969.This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).